Radiation Oncology

Latest News

Hypofractionation Noninferior to Conventional Radiotherapy for Low-Risk Prostate Cancer
Hypofractionation Noninferior to Conventional Radiotherapy for Low-Risk Prostate Cancer

July 8th 2024

Hypofractionated radiotherapy was noninferior to conventional radiotherapy in patients with low-risk prostate cancer.

PSMA Response May Indicate Better Metastasis Control in Oligometastatic CSPC
PSMA Response May Indicate Better Metastasis Control in Oligometastatic CSPC

July 7th 2024

radiation
TUG Test Can Be Feasibly Implemented in Radiology Workflows to Promote Fall Risk Prevention

December 27th 2023

Despite Treatment Advances, Oral Mucositis Continues to Plague Patients With Head and Neck Cancer
Despite Treatment Advances, Oral Mucositis Continues to Plague Patients With Head and Neck Cancer

November 21st 2023

SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma
SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma

October 13th 2023

Video Interviews
Latest CME Events & Activities

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.